Chong Kun Dang Pharmaceutical Corp
185750
Company Profile
Business description
Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).
Contact
368 Chungjungro-3Ga
Seodaemun-gu
Seoul120-756
KORT: +82 221940300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
2,336
Stocks News & Analysis
stocks
Unconventional wisdom: Are dividends the answers?
As investors toil in complexity the obvious solution may be the right one.
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,934.30 | 45.10 | -0.50% |
| CAC 40 | 7,834.58 | 16.30 | 0.21% |
| DAX 40 | 24,217.50 | 78.43 | -0.32% |
| Dow JONES (US) | 44,901.92 | 208.01 | 0.47% |
| FTSE 100 | 9,120.31 | 18.06 | -0.20% |
| HKSE | 25,388.35 | 278.83 | -1.09% |
| NASDAQ | 21,108.32 | 50.36 | 0.24% |
| Nikkei 225 | 41,456.23 | 370.11 | -0.88% |
| NZX 50 Index | 12,853.46 | 48.33 | 0.38% |
| S&P 500 | 6,388.64 | 25.29 | 0.40% |
| S&P/ASX 200 | 8,666.90 | 42.50 | -0.49% |
| SSE Composite Index | 3,593.66 | 12.07 | -0.33% |